2014 News Releases

Webcast ImageWebcast
Zogenix, Inc. at Oppenheimer 27th Annual Healthcare Conference (Replay)
03/22/17 at 2:10 p.m. ET
Zogenix, Inc. at Oppenheimer 27th Annual Healthcare Conference
Wednesday, March 22, 2017 2:10 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/03/14Zogenix to Participate in Oppenheimer 25th Annual Healthcare Conference
SAN DIEGO, Dec. 3, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced that Stephen Farr, President, and Ann Rhoads, Chief Financial Officer, will present at the Oppenheimer 25th Annual Healthcare Conference in New York, NY on December 10, 2014. Event: Oppenheimer 25th Annual Healthcare Conference Date:   Wednesday, Dec... 
Printer Friendly Version
12/01/14Results of Long-Term, Open-Label Study Published in the Journal of Pain Research Demonstrate the Safety, Tolerability and Effectiveness of Zohydro(R) ER
Findings Contribute to Growing Body of Evidence Supporting Efficacy and Safety Profile SAN DIEGO, Dec. 1, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced the publication of a long-term Phase 3 open-label study, which showed that Zohydro® ER (hydrocodone bitartrate) Extended-Release Capsules, CII, were generally safe, well-tolerated ... 
Printer Friendly Version
11/12/14Zogenix to Participate in Stifel 2014 Healthcare Conference
SAN DIEGO, Nov. 12, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced that Zogenix management will present at the Stifel 2014 Healthcare Conference in New York, NY on November 18, 2014. Event: Stifel 2014 Healthcare Conference Date: Tuesday, November 18, 2014 ... 
Printer Friendly Version
11/06/14Zogenix Reports Third Quarter 2014 Financial Results
Conference Call and Webcast Today, November 6, at 4:30 p.m. ET Recent Business Highlights Submitted a supplemental New Drug Application (sNDA) for a modified formulation with potential abuse deterrent properties of Zohydro® ER (hydrocodone bitartrate) Extended-Release Capsules, CII, on September 30, with a target action date in late January 2015   Acquired Brabant Pharma, obtaining global rights for a Phase 3 product candidate with orphan drug designation in the U.S. and ... 
Printer Friendly Version
10/31/14Zogenix and Purdue Pharma Exchange Waivers of Regulatory Exclusivity for Extended-Release Hydrocodone Products
SAN DIEGO, Oct. 31, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced it has entered into an agreement with Purdue Pharma L.P. (Purdue) under which the two companies have exchanged waivers of regulatory exclusivity applicable to their respective single-entity, extended-release hydrocodone products. These waivers are applicable to curre... 
Printer Friendly Version
10/30/14Zogenix Announces Conference Call and Webcast to Present Third Quarter 2014 Financial Results
Conference Call Scheduled for November 6, 2014 at 4:30 pm ET SAN DIEGO, Oct. 30, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced it will release financial results for the third quarter ended September 30, 2014, after the market closes on Thursday November 6, 2014, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m... 
Printer Friendly Version
10/27/14Zogenix Acquires U.K.-Based Brabant Pharma
Obtains global rights for treatment option in development for Dravet syndrome, a rare and catastrophic form of epilepsy that begins in infancy Plans to initiate Phase 3 clinical studies of Brabafen™ in second quarter of 2015 Conference call and webcast today, October 27, at 4:30 pm ET SAN DIEGO, Calif., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous s... 
Printer Friendly Version
10/01/14Zogenix Submits Modified Formulation of Zohydro(R) ER With Potential Abuse Deterrent Properties for FDA Review
SAN DIEGO, Oct. 1, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced it has submitted to the U.S. Food and Drug Administration (FDA) a supplemental New Drug Application (sNDA) for a modified formulation of Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII, which has been designed to have abuse deterrent properties. The... 
Printer Friendly Version
09/18/14New Data Shows Zohydro(R) ER Reduced Pain and Improved Function in People With Chronic Pain
Moderate and Substantial Levels of Pain Relief Produce the Greatest Functional Benefits With Zohydro(R) ER (hydrocodone bitartrate) Extended-Release Capsules, CII PHOENIX, Sept. 18, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today presented data from a one year open label study that demonstrated chronic pain patients who achieved substantial l... 
Printer Friendly Version
09/04/14Education, Patient-Focused Approach to Treating Chronic Pain Are Keys to Preventing Opioid Abuse, Say Experts, Patients
Patients Want Access to a Full Range of FDA-Approved Medications and Pain Relief That Lasts for the Duration of the Prescribed Dosing SAN DIEGO, Sept. 4, 2014 (GLOBE NEWSWIRE) -- When leading health care professionals, chronic pain patients and pain community advocates gathered recently to kick off National Pain Awareness Month, their discussions quickly turned to the challenge of balancing public health concerns about opioid abuse and the unmet medical needs of millions of Americans whose dail... 
Printer Friendly Version
09/02/14Zogenix to Participate in Morgan Stanley Global Healthcare Conference 2014
SAN DIEGO, Sept. 2, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced that Zogenix management will present at the Morgan Stanley Global Healthcare Conference 2014 in New York, NY on September 10, 2014. Event: Morgan Stanley Global Healthcare Conference 2014 Date: Wednesday, September 10, 2014 Place: New York City T... 
Printer Friendly Version
09/02/14Zohydro(R) ER Demonstrates Sustained 12-Hour Pain Relief
No Additional Nighttime Dosing and No End-of-Dose Failure, in Most Patients, According to Post-Hoc Analysis Presented at PAINWeek SAN DIEGO, Sept. 2, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced new post-hoc analysis data showing that the indicated 12-hour dose of Zohydro® ER, (hydrocodone bitartrate) Extended-Release Capsules, C... 
Printer Friendly Version
08/05/14Zogenix Reports Second Quarter 2014 Financial Results
Conference Call and Webcast Today, August 5, at 4:30 p.m. ET Recent Business Highlights Provided updated timeline for abuse deterrent formulations of Zohydro® ER (hydrocodone bitartrate) Extended-Release Capsules, CII, with sNDA for first candidate expected to be filed by October, with potential approval in early 2015 Completed sale of SUMAVEL® DosePro® migraine therapy business to Endo International plc for $89.6 million in cash, milestone payments of up to $20 million, and ap... 
Printer Friendly Version
08/01/14Zogenix Announces Departure of Chief Commercial Officer, Scott Shively
SAN DIEGO, Aug. 1, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced that Scott Shively has resigned as Chief Commercial Officer in order to pursue another opportunity. In the interim, Roger Hawley, the Company's Chief Executive Officer, will assume the duties and responsibilities of the Chief Commercial Officer and lead the conti... 
Printer Friendly Version
07/22/14Zogenix Announces Conference Call and Webcast to Present Second Quarter 2014 Financial Results
Conference Call Scheduled for August 5, 2014 at 4:30 pm ET SAN DIEGO, July 22, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced it will release financial results for the second quarter ended June 30, 2014, after the market closes on Tuesday, August 5, 2014, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), t... 
Printer Friendly Version
07/17/14Zogenix Announces Appointment of David Brushwood, J.D., R.Ph., to External Safe Use Board
Board Commends Comprehensive Surveillance Program, Educational Efforts for Zohydro(R) ER SAN DIEGO, July 17, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced that David Brushwood, J.D., R.Ph., recently-retired Professor Emeritus of Pharmaceutical Outcomes and Policy at the University of Florida, College of Pharmacy, has joined t... 
Printer Friendly Version
07/14/14Zogenix Announces New Patent Valid Through 2032 For DosePro(R) Needle-Free Delivery System
Covers Fundamental Delivery Profile Needed to Achieve Reliable Subcutaneous Jet Injection SAN DIEGO, July 14, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) announced today the issuance of a new patent, US 8,734,384, from the United States Patent and Trademark Office (USPTO). The patent covers the biphasic pressure profile utilized by the company's proprietary DosePro® Needle-free Delivery System. The specific pressure profile covered is essential for reliable subcutaneous injection by ne... 
Printer Friendly Version
07/09/14Zogenix Reports Positive Development on U.S. District Court Ruling
Judge Upholds Prior Decision That State Regulations Cannot Usurp Federal Law SAN DIEGO, July 9, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today commented on the order issued by the U.S. District Court in Massachusetts upholding its prior decision that imposing regulations to restrict access to Zohydro® ER (hydrocodone bitartrate) Extended-Release Capsules, CII, violates Constitutional law.   "This ruling upholds the important principle that a state cannot take action that could r... 
Printer Friendly Version
07/02/14Zogenix Provides Update on Development of Abuse Deterrent Formulations of Zohydro(R) ER
Application for Next Generation of Zohydro(R) ER to be Filed by October 2014 SAN DIEGO, July 2, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced an update on its development programs focused on the introduction of abuse deterrent formulations of Zohydro® ER (hydrocodone bitartrate) Extended-Release Capsules, CII. Zohydro ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment ... 
Printer Friendly Version
06/16/14Zogenix to Present at Two Upcoming Conferences
SAN DIEGO, June 16, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced that Ann Rhoads, Chief Financial Officer, will be presenting at two upcoming institutional investor conferences. The first conference is the Wells Fargo 2014 Healthcare Conference on June 18, 2014 in Boston, MA. Event: Wells Fargo 2014 Healthcare Conference ... 
Printer Friendly Version
06/02/14Zogenix Reports Granting of Inducement Awards
SAN DIEGO, June 2, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, reported today that it has issued inducement awards to four new non-executive employees. The awards were made on June 2, 2014 under Zogenix's Employment Inducement Equity Incentive Award Plan, which provides for the granting of equity awards to new employees of Zogenix. The ... 
Printer Friendly Version
06/02/14Zogenix Officers to Report Withholding of Shares
SAN DIEGO, June 2, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, announced today that certain of its executive officers will submit Form 4 filings pursuant to Section 16 of the Securities Exchange Act of 1934.   Under Zogenix's 2010 Equity Incentive Award Plan, certain of its employees, including certain executive officers, previously received... 
Printer Friendly Version
05/30/14Zogenix to Present at Jefferies 2014 Global Healthcare Conference
SAN DIEGO, May 30, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced that Stephen Farr, Ph.D., President, and Ann Rhoads, Chief Financial Officer, will be presenting at the Jefferies 2014 Global Healthcare Conference in New York City on June 4, 2014. Event: Jefferies 2014 Global Healthcare Conference Date: Wednesday, June 4, 20... 
Printer Friendly Version
05/19/14Zogenix Closes Sale of SUMAVEL(R) DosePro(R) Migraine Therapy to Endo International
SAN DIEGO, May 19, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, announced today the closing of its previously announced sale of its SUMAVEL® DosePro® Needle-free Delivery System (sumatriptan injection) product line to Endo International plc (Nasdaq:ENDP) for $85 million in cash and milestone payments of up to $20 million. The SUMAVEL DosePro ... 
Printer Friendly Version
05/08/14Zogenix Reports First Quarter 2014 Financial Results
Conference Call and Webcast Today, May 8, at 4:30 p.m. ET Recent Business Highlights Commercial and medical affairs organization began educational efforts to prescribers and pharmacists for Zohydro™ ER (hydrocodone bitartrate) extended-release capsules the first week in March Continued efforts to support patient access to Zohydro ER in all States Entered definitive agreement to sell SUMAVEL® DosePro® migraine therapy business to Endo International plc for $85 million in c... 
Printer Friendly Version
05/02/14Zogenix Reports Granting of Inducement Awards
SAN DIEGO, May 2, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, reported today that it has issued inducement awards to five new non-executive employees. The awards were made on May 1, 2014 under Zogenix's Employment Inducement Equity Incentive Award Plan, which provides for the granting of equity awards to new employees of Zogenix. The in... 
Printer Friendly Version
04/30/14Zogenix Announces Conference Call and Webcast to Present First Quarter 2014 Financial Results
Conference Call Scheduled for May 8, 2014 at 4:30 pm ET SAN DIEGO, April 30, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced it will release financial results for the first quarter ended March 31, 2014, after the market closes on Thursday, May 8, 2014, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to di... 
Printer Friendly Version
04/24/14Zogenix Announces Sale of SUMAVEL(R) DosePro(R) Migraine Therapy to Endo International
Conference Call Scheduled for 8:30 am ET on Thursday, April 24, 2014 SAN DIEGO, April 24, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, announced today that it has entered a definitive agreement to sell its SUMAVEL® DosePro® Needle-free Delivery System (sumatriptan injection) migraine therapy business to Endo International plc (Nasdaq:ENDP) for $... 
Printer Friendly Version
04/24/14A Common Sense Approach to Appropriate Drug Use
SAN DIEGO, April 24, 2014 /PRNewswire/ -- We at Zogenix  have reviewed the letter to Vermont Governor Peter Shumlin signed by the Center for Lawful Access and Abuse Deterrence (CLAAD),  The American Academy of Pain Management and the National Fibromyalgia & Chronic Pain Association, which asks the Governor and health commissioner to participate in a "multi-lateral meeting to develop a more thorough approach" to stemming Vermont's prescription drug abuse epidemic. We agree with and commit our... 
Printer Friendly Version
04/23/14Zogenix Responds to Governor's Action Singling Out Zohydro™ ER in Massachusetts, Encourages Officials to Consider Patient Needs and Effective Class-Wide Measures
SAN DIEGO, April 23, 2014 /PRNewswire/ -- Zogenix will continue to work to ensure patients suffering from severe chronic pain have access to the FDA-approved medications they need in every state nationwide, including Massachusetts. We are once again disappointed that Governor Patrick would issue another immediate restriction without first accepting our offer to discuss the facts and work together to address the needs of patients while combating abuse and addiction. We fully support appropriat... 
Printer Friendly Version
04/15/14Zogenix Announces Ruling Preventing the Implementation of Massachusetts Governor's Order that Blocked Access to Zohydro™ ER
SAN DIEGO, April 15, 2014 /PRNewswire/ -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced that the U.S. District Court in Massachusetts entered an order, preventing the implementation of the Commonwealth's ban of Zohydro™ ER on Constitutional grounds.  This order will become effective on April 22, 2014. The court decision today supports the importance of... 
Printer Friendly Version
04/08/14Zogenix Update on Legal Action
SAN DIEGO, April 8, 2014 /PRNewswire/ -- Today Zogenix presented its case in U.S. District Court in Boston requesting an immediate order staying the ban on the U.S. Food and Drug Administration (FDA)-approved prescription drug product, Zohydro™ ER (hydrocodone bitartrate) extended-release capsules (CII), entered on March 27, 2014, by Massachusetts Governor Deval Patrick. Zogenix appreciates the opportunity to be heard by the court on an expedited basis. A follow-up hearing has been scheduled for... 
Printer Friendly Version
04/07/14Zogenix Takes Legal Action in Federal Court to Block Massachusetts Improper Ban on Zohydro™ ER
Company Files for Injunction - Prescription Drug Status Should Reside Solely With the FDA SAN DIEGO, April 7, 2014 /PRNewswire/ --  Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today filed a lawsuit in the U.S. District Court in Massachusetts requesting the court to grant a temporary restraining order against execution of the executive order recently announced by G... 
Printer Friendly Version
04/04/14FDA, HHS Reaffirm Support for Chronic Pain Patients Amid Zohydro ER Debate
SAN DIEGO, April 4, 2014 /PRNewswire/ -- Today, Health and Human Services (HHS) Secretary Kathleen Sebelius, and U.S. Food and Drug Administration (FDA) Commissioner Dr. Margaret Hamburg, called for a balanced approach in the fight against prescription drug abuse and preserving the protection of the needs and rights of patients suffering from severe chronic pain. It was an impressive showcase of a unified front and a call for all stakeholders to help at every level. It is vitally important fo... 
Printer Friendly Version
04/02/14Zogenix Statement: Let's Get the Facts Straight About Zohydro ER
SAN DIEGO, April 2, 2014 /PRNewswire/ -- We are extremely disappointed that the U.S. Drug Enforcement Administration (DEA) Administrator, as she did in a Congressional hearing today, would repeat misinformation about Zohydro™ ER that has been demonstrated to be false. As informed health care experts and the U.S. Food and Drug Administration have noted for the record, Zohydro ER is no more potent than any other hydrocodone medication available. The facts are clear: Zohydro ER is the same hy... 
Printer Friendly Version
04/02/14Zogenix Reports Granting of Inducement Awards
SAN DIEGO, April 2, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, reported today that it has issued inducement awards to two new non-executive employees. The awards were made on April 1, 2014 under Zogenix's Employment Inducement Equity Incentive Award Plan, which provides for the granting of equity awards to new employees of Zogenix. The... 
Printer Friendly Version
03/27/14Zogenix Statement: Massachusetts Denies Patients a Legitimate Option for Severe Chronic Pain
SAN DIEGO, March 27, 2014 /PRNewswire/ -- We agree with Governor Deval Patrick's intention to curb the epidemic of drug abuse in Massachusetts. However, we are extremely concerned by his unprecedented action with respect to a specific FDA-approved prescription medication. We believe Governor Patrick's ban on Zohydro™ ER only serves to unfairly restrict patient access to the only hydrocodone pain reliever available for long-term, daily, severe chronic pain patients who are obtaining relief wi... 
Printer Friendly Version
03/26/14Zogenix Appoints James Breitmeyer to Its Board of Directors
SAN DIEGO, March 26, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, announced today that James B. Breitmeyer, M.D., Ph.D., has been appointed as a new member of the Company's Board of Directors. Cam L. Garner, Chairman of the Board, said, "We are pleased to welcome Dr. Breitmeyer to the Zogenix Board of Directors. He has a strong track rec... 
Printer Friendly Version
03/07/14Dr. Marsha Stanton Receives 2014 American Academy of Pain Medicine Distinguished Service Award
SAN DIEGO, March 7, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced that the American Academy of Pain Medicine (AAPM) has presented Marsha R. Stanton, Ph.D., RN, Executive Director of Medical Affairs at Zogenix, with the Distinguished Service Award, recognition given annually to honor an individual for their outstanding commitment an... 
Printer Friendly Version
03/05/14Zogenix Reports Fourth Quarter and Full Year 2013 Financial Results
Conference Call and Webcast Today, March 5, at 4:30 p.m. ET Business Highlights and Milestones Raised net proceeds of $64.5 million in a public offering of common stock Expanded medical and commercial leadership teams, and sales force to 150 representatives Completed preparations for responsible commercialization efforts for Zohydro™ ER (hydrocodone bitartrate) extended release capsules for the management of pain severe enough to require daily, around-the-clock, long-term... 
Printer Friendly Version
03/05/14Zogenix Reports Granting of Inducement Awards
SAN DIEGO, March 5, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, reported today that it has issued inducement awards to 102 new non-executive employees. The awards were made on March 3, 2014 under Zogenix's Employment Inducement Equity Incentive Award Plan, which provides for the granting of equity awards to new employees of Zogenix. The... 
Printer Friendly Version
02/27/14Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and Full Year 2013 Financial Results
Conference Call Scheduled for March 5, 2014 at 4:30 pm ET SAN DIEGO, Feb. 27, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced it will release financial results for the fourth quarter and full year ended December 31, 2013, after the market closes on Wednesday, March 5, 2014, and will hold a conference call on this day at 4:30 p.... 
Printer Friendly Version
02/13/14Data From Zohydro(TM) ER (hydrocodone bitartrate) Phase 3 Clinical Trial Published in Pain Medicine Demonstrates Its Benefit as a Therapeutic Option for the Management of Pain Severe Enough to Require Daily, Around-the-Clock, Long-Term Opioid Treatment and for Which Alternative Treatment Options Are Inadequate
SAN DIEGO, Feb. 13, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced the publication of results from the Phase 3 clinical study of ZohydroTM ER (hydrocodone bitartrate) extended-release capsules, which were originally reported in 2011 and were used as the basis for the Zohydro ER new drug application ("NDA"), which was approved b... 
Printer Friendly Version
02/12/14Zogenix Establishes External Safe-Use Board
Experts to Provide Independent Oversight and Recommendations SAN DIEGO, Feb. 12, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced the formation of an External Safe-Use Board. The Board will be a key part of the company's comprehensive approach supporting the appropriate use of ZohydroTM ER (hydrocodone bitartrate) extended-release ca... 
Printer Friendly Version
02/11/14Zogenix Provides Update on Zohydro(TM) ER (hydrocodone bitartrate) Launch Readiness Plans
Zogenix in Final Preparations for Early March Market Launch SAN DIEGO, Feb. 11, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced it has made significant progress in preparing for the market launch of ZohydroTM ER (hydrocodone bitartrate) extended-release capsules, approved by the U.S. Food and Drug Administration in October 2013... 
Printer Friendly Version
02/04/14Zogenix to Present at Leerink Swann 2014 Global Healthcare Conference
SAN DIEGO, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, today announced that Stephen J. Farr, Ph.D., President, and Ann Rhoads, Chief Financial Officer, will be presenting at the Leerink Swann 2014 Global Healthcare Conference in New York on February 12, 2014. Event: Leerink Swann 2014 Global Healthcare Conference Date: Wednesday, Februar... 
Printer Friendly Version
02/04/14Zogenix Reports Granting of Inducement Awards
SAN DIEGO, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, reported today that it has issued inducement awards to fourteen new non-executive employees. The awards were made on February 3, 2014 under Zogenix's Employment Inducement Equity Incentive Award Plan, which provides for the granting of equity awards to new employees of Zogenix. The inducement ... 
Printer Friendly Version
01/13/14Zogenix Announces Preliminary Fourth Quarter 2013 Gross Product Sales
SAN DIEGO, Jan. 13, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, announced today preliminary unaudited gross product sales on sales of SUMAVEL® DosePro® for the quarter ended December 31, 2013. Zogenix expects to report fourth quarter 2013 gross product sales of approximately $14 million on 141,780 units shipped, with unit volume up approximately 2.2% sequenti... 
Printer Friendly Version
01/09/14Zogenix and Mallinckrodt Agree to End Co-Promotion for SUMAVEL(R) DosePro(R) Effective January 31, 2014
SAN DIEGO, Jan. 9, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, and Mallinckrodt (NYSE:MNK) announced today that the co-promotion of SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System will end on January 31, 2014. SUMAVEL DosePro is Zogenix's first commercial product and was launched in January 2010 for the acute treatment of migraine and cl... 
Printer Friendly Version
01/07/14Zogenix Reports Granting of Inducement Awards
SAN DIEGO, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, reported today that it has issued inducement awards to two new non-executive employees. The awards were made on January 2, 2014 under Zogenix's Employment Inducement Equity Incentive Award Plan, which provides for the granting of equity awards to new employees of Zogenix. The inducement awards... 
Printer Friendly Version